AWAngela J. Waanders

Angela J. Waanders

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angela J. Waanders has a total of 394 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Data to Duty: An Informatics Blueprint for Pediatric Oncology Trials

    by Kirk D. Wyatt, Andrew D. Tran, Suzi Birz, Michael Watkins, Jeremy L. Warner, Heather Wasserstrom, Grace E. Rossi, Elyssa Rubin, Charles A. Phillips, Angela J. Waanders, et al.

    The data generated by cooperative‐group clinical trials have transformed outcomes for children with cancer, yet the infrastructure underlying their collection and use has not kept pace with advances in informatics and data science. Data collection on pediatric oncology trials remains largely manual: Clinical research assistants abstract values from medical records and key them into electronic case report forms, a process that is costly, slow, inconsistent, and error‐prone. Data are often siloed within trial networks for years after a study closes, limiting their value for secondary research, particularly for rare cancers. In this consensus blueprint, an interdisciplinary group of pediatric oncologists, clinical informaticians, data scientists, nurses, clinical research assistants, drug developers, and parent advocates outlines a pragmatic path forward across three components of the data lifecycle: collection, processing, and sharing. We argue that case report forms should be bound to standardized common data elements; that automated data abstraction from electronic health records, including via large language models with human‐in‐the‐loop validation, should replace much of today's manual abstraction; that paper chemotherapy roadmaps should be reconceived as computable artifacts; and that clinical trials data should be deposited in publicly accessible repositories with appropriate governance as soon as practically feasible. We discuss facilitators and barriers within each component, including standards adoption, regulatory complexity, financial sustainability, and workforce capacity. We propose concrete actions for funders, clinical trials networks, professional societies, and industry. The technology to achieve these goals exists today, and widespread adoption requires coordinated leadership, sustainable funding models, and a cultural shift that recognizes data stewardship as an ethical imperative and a duty to the children and families we serve.

  • Open Access

    Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric central nervous system tumors

    by Ryan J. Corbett, Rebecca S. Kaufman, Shelly W. McQuaid, Zalman Vaksman, Saksham Phul, Miguel A. Brown, Jennifer L. Mason, Sebastian M. Waszak, Bo Zhang, Chuwei Zhong, et al.

    The contribution of rare pathogenic/likely pathogenic (P/LP) germline variants to pediatric central nervous system (CNS) tumor development remains understudied. Here, we characterize the prevalence and biological significance of germline P/LP variants in cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBTA). We identify germline P/LP variants in 23.3% (193/830) of patients and the majority (137/193) lack clinical reporting of genetic tumor syndromes. Among P/LP carriers, 34.6% have putative somatic second hits or loss of function tumor alterations. Finally, we link pathogenic germline variation with somatic events and patient survival to highlight the impact of germline variation on tumorigenesis and patient outcomes.


  • Open Access

    Novel SMARCA4 Variant in an Infant With Atypical Teratoid Rhabdoid Tumor

    by Shria K. Bs Haldipurkar, Sudarshawn N. Do Damodharan, Pamela Rathbun, Kai Lee Yap, Nitin Wadhwani, Angela J. Waanders

    Atypical teratoid/rhabdoid tumors (AT/RT) are malignant central nervous system (CNS) tumors. Typically, AT/RT is classified as SMARCB1 (INI-1) deficient or as SMARCA4 (BRG1) deficient. In this case, we describe a unique case of AT/RT with a novel SMARCA4 missense variant identified on next-generation sequencing but retained expression of INI-1 and BRG-1 on immunohistochemistry. Diagnosis of the tumor and discovery of the novel SMARCA4 variant was only possible after comprehensive tumor molecular testing tailored for pediatric malignancies. This case highlights the importance of molecular genetic testing as part of a workup in neoplasms concerning for possible AT/RT.


  • Open Access

    Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumors

    by Ryan J. Corbett, Rebecca S. Kaufman, Shelly W. McQuaid, Zalman Vaksman, Saksham Phul, Miguel A. Brown, Jennifer L. Mason, Sebastian M. Waszak, Bo Zhang, Chuwei Zhong, et al.

    The contribution of rare pathogenic/likely pathogenic (P/LP) germline variants to pediatric central nervous system (CNS) tumor development remains understudied. Here, we characterized the prevalence and clinical significance of germline P/LP variants in cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBTA). We identified germline P/LP variants in 23.3% (193/830) of patients and the majority (137/193) lacked clinical reporting of genetic tumor syndromes. Among P/LP carriers, 34.6% had putative somatic second hits or loss of function tumor alterations. Finally, we linked pathogenic germline variation with novel somatic events and patient survival to highlight the impact of germline variation on tumorigenesis and patient outcomes.

  • Open Access

    Genetic ancestry superpopulations show distinct prevalence and outcomes across pediatric central nervous system tumors from the Pediatric Brain Tumor Atlas and Pediatric Neuro-Oncology Consortium

    by Ryan J Corbett, Cricket C Gullickson, Zhuangzhuang Geng, Miguel A Brown, Bo Zhang, Chuwei Zhong, Nicholas Van Kuren, Antonia Chroni, Christopher Blackden, Ammar S Naqvi, et al.

    Background: Central nervous system (CNS) tumors lead to cancer-related mortality in children. Genetic ancestry-associated cancer prevalence and outcomes have been studied but are limited. Methods: We performed genetic ancestry prediction in 1,452 pediatric patients with paired normal and tumor whole genome sequencing from the Open Pediatric Cancer (OpenPedCan) project to evaluate the influence of reported race and ethnicity and ancestry-based genetic superpopulations on tumor histology, molecular subtype, survival, and treatment. Results: Predicted superpopulations included African (AFR, N = 153), Admixed American (AMR, N = 222), East Asian (EAS, N = 67), European (EUR, N = 968), and South Asian (SAS, N = 42). Reported race and ethnicity and ancestry-based genetic superpopulations were non-randomly associated (P < .001). Patients with an atypical teratoid rhabdoid tumor or meningioma were enriched for AFR ancestry (OR = 2.6, FDR = 0.01; OR = 2.9, FDR = 0.01, respectively). Among KIAA1549::BRAF fusion-positive low-grade glioma (LGG) diagnoses, EAS and SAS patients disproportionately harbored exon 15:09 breakpoints (FDR < 0.05), and AMR patients demonstrated rare breakpoints, which were associated with lesser degree of surgical resection and worse event-free survival (EFS) versus other breakpoints (hazard ratio (HR) = 4.6, P = .03). Non-EUR and AMR patients with germ cell tumors and SHH-activated medulloblastoma, respectively, exhibited worse EFS relative to EUR patients (HR = 12.1, P < .01; HR = 5.2, P = .03) and AFR patients with LGG (HR = 16.4, P < .01) or ependymoma (HR = 5.5, P = .02) had worse overall survival compared to EUR patients. We observed a higher frequency of clinical trial enrollment among AMR patients across tumor histologies (OR = 2.0, P ≤ .01), but increased utilization of photon versus proton radiation relative to other superpopulations (OR = 0.55, P= .04). Conclusions: Genetic ancestry-associated differences exist across pediatric CNS tumor histological and molecular subtypes from PBTA and PNOC. Further investigation into genetic and socioeconomic factors contributing to these observed inequities is needed.


  • Socioeconomic Factors Associated With Participation in Postmortem Tissue Donation in Pediatric Central Nervous System Tumors

    by Judith M. Kabat, Lauren K. Boland, Melissa Williams, Ian Michelson, Alicia Lenzen, Ashley S. Plant‐Fox, Nitin Wadhwani, Angela J. Waanders

    Background: The gift of postmortem tissue donation is critical to pediatric central nervous system (CNS) research. As a “Center of Excellence” for the Gift from a Child Program, our institution has a well‐established postmortem tissue donation program. Our objective was to determine if differences exist between patients who participated in and those that declined research‐based autopsy.Procedure: We performed a single‐institution retrospective chart review of pediatric patients with CNS malignancies who died from their disease between January 1, 2021 and December 31, 2022. Individual clinical, demographic, and socioeconomic data were assessed. Population‐level data were estimated using Zip Code Tabulation Areas. Descriptive statistics were used to compare categorical data.Results: Among the 23 patient families approached during the study time frame, 8/23 (35%) consented to participation. In the consented (C) versus declined (D) group, there was a higher percentage of White, non‐Hispanic/Latino patients by self‐reported race (C: 88% vs. D: 55%), and no patients who identified as Asian or Hispanic/Latino (C: 0% and 0% vs. D: 13% and 27%). Of all patients approached, two required interpreters (9%), and both families declined participation. The rate of private insurance was higher in the consented group (C: 75% vs. D: 47%) compared to Medicaid as primary insurance in the declined group (C: 13% vs. D: 53%). Conclusions: Future research should aim to understand and improve identified disparities to ensure research advancements benefit all children with CNS malignancies. One area we plan to address is improved communication with non‐English‐speaking families by partnering with our interpreter services.


  • Open Access

    “Socioeconomic factors associated with participation in post-mortem tissue donation in pediatric central nervous system (CNS) tumors”

    by Judith Kabat, Lauren K. Boland, Melissa Williams, Ian Michelson, Alicia Lenzen, Ashley Plant, Nitin Wadhwani, Angela Waanders

    Background : The gift of post-mortem tissue donation is critical to pediatric CNS research. As a “Center of Excellence” for the Gift from a Child Program, our institution has a well-established post-mortem tissue donation program. Our objective was to determine if differences exist between patients that participated in and those that declined research-based autopsy. Procedure: We performed a single-institution retrospective chart review of pediatric patients with CNS malignancies who died from their disease between 1/1/2021 and 12/31/2022. Individual clinical, demographic, and socioeconomic data were assessed. Population-level data were estimated using Zip Code Tabulation Areas. Descriptive statistics were used to compare categorical data. Results : Among the 23 patient families approached during the study time frame, 8/23 (35%) consented to participation. In the consented (C) vs. declined (D) group, there was a higher percentage of White, Non-Hispanic/Latino patients by self-reported race (C: 88% vs. D: 55%) and no patients who identified as Asian or Hispanic/Latino (C: 0% & 0% vs. D: 13% & 27%). Of all patients approached, 2 required interpreters (9%) and both families declined participation. The rate of private insurance was higher in the consented group (C: 75% vs D: 47%) compared to Medicaid as primary insurance in the declined group (C: 13% vs D: 53%). Conclusions : Future research should aim to understand and improve identified disparities to ensure research advancements benefit all children with CNS malignancies. One area we plan to address is improved communication with non-English speaking families by partnering with our interpreter services.

  • Open Access

    Genetic ancestry superpopulations show distinct prevalence and outcomes across pediatric central nervous system tumors from the PBTA and PNOC

    by Ryan J. Corbett, Cricket C. Gullickson, Zhuangzhuang Geng, Miguel A. Brown, Bo Zhang, Chuwei Zhong, Nicholas Van Kuren, Antonia Chroni, Christopher Blackden, Ammar S. Naqvi, et al.

    Background: Central nervous system (CNS) tumors lead to cancer-related mortality in children. Genetic ancestry-associated cancer prevalence and outcomes have been studied, but is limited. Methods: We performed genetic ancestry prediction in 1,454 pediatric patients with paired normal and tumor whole genome sequencing from the Open Pediatric Cancer (OpenPedCan) project to evaluate the influence of reported race and ethnicity and ancestry-based genetic superpopulations on tumor histology, molecular subtype, survival, and treatment. Results: Predicted superpopulations included African (AFR, N=153), Admixed American (AMR, N=223), East Asian (EAS, N=67), European (EUR, N=968), and South Asian (SAS, N=43). Reported race and ethnicity and ancestry-based genetic superpopulations were non-randomly associated. Patients with an atypical teratoid rhabdoid tumor or meningioma were enriched for AFR ancestry. Patients of AMR ancestry with KIAA1549::BRAF fusion-positive low-grade glioma (LGG) had tumors enriched for rare fusion breakpoints, lesser extent of surgical resection, and worse event-free survival (EFS). Non-EUR and AMR patients with germ cell tumors or SHH- activated medulloblastoma exhibited worse EFS relative to EUR patients, and patients of AFR ancestry with LGG or ependymoma had worse overall survival compared to EUR patients. We observed higher frequency of clinical trial enrollment among AMR patients across tumor histologies, but increased utilization of photon versus proton radiation relative to other superpopulations. Conclusions: Genetic ancestry-associated differences exist across pediatric CNS tumor histological and molecular subtypes. Further investigation into genetic and socioeconomic factors contributing to these observed inequities is needed. Key Points: Distinct associations of genetic ancestry-based superpopulations exist within pediatric CNS tumor histologic and molecular subtypes and correlate with survival outcomes and treatment. Importance of the Study: This work provides critical insight on the impact of reported race and ethnicity and genetic-based ancestry superpopulations on nearly 1,500 pediatric patients with CNS tumors who had matched normal and tumor sequencing performed. We identify novel associations between ancestry superpopulations and tumor histology, molecular subtypes, and treatments received. Here, we begin to inform on the contributions of social constructs of race and ethnicity and tumor characteristics that are enriched among genetic-based ancestry superpopulations on clinical outcomes of pediatric patients with CNS tumors. Our findings indicate that potential social and genetic risk stratifications exist for pediatric CNS tumors and warrant further investigation to ensure equitable clinical outcomes for all patients.

  • Open Access

    The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science

    by Jena V. Lilly, Jo Lynne Rokita, Jennifer L. Mason, Tatiana Patton, Stephanie Stefankiewiz, David Higgins, Gerri Trooskin, Carina A. Larouci, Kamnaa Arya, Elizabeth Appert, et al.


  • Open Access

    The Children’s Brain Tumor Network (CBTN) - Accelerating Research in Pediatric Central Nervous System Tumors through Collaboration and Open Science

    by Jena V. Lilly, Jo Lynne Rokita, Jennifer L. Mason, Tatiana Patton, Stephanie Stefankiewiz, David Higgins, Gerri Trooskin, Carina A. Larouci, Kamnaa Arya, Elizabeth Appert, et al.

    Pediatric brain tumors are the leading cause of cancer-related death in children in the United States and contribute a disproportionate number of potential years of life lost compared to adult cancers. Moreover, survivors frequently suffer long-term side effects, including secondary cancers. The Children’s Brain Tumor Network (CBTN) is a multi-institutional international clinical research consortium created to advance therapeutic development through the collection and rapid distribution of biospecimens and data via open-science research platforms for real-time access and use by the global research community. The CBTN’s 32 member institutions utilize a shared regulatory governance architecture at the Children’s Hospital of Philadelphia to accelerate and maximize the use of biospecimens and data. As of August 2022, CBTN has enrolled over 4,700 subjects, over 1,500 parents, and collected over 65,000 biospecimen aliquots for research. Additionally, over 80 preclinical models have been developed from collected tumors. Multi-omic data for over 1,000 tumors and germline material is currently available with data generation for > 5,000 samples underway. To our knowledge, CBTN provides the largest open-access pediatric brain tumor multi-omic dataset annotated with longitudinal clinical and outcome data, imaging, associated biospecimens, child-parent genomic pedigrees, and in vivo and in vitro preclinical models. Empowered by NIH-supported platforms such as the Kids First Data Resource and the Childhood Cancer Data Initiative, the CBTN continues to expand the resources needed for scientists to accelerate translational impact for improved outcomes and quality of life for children with brain and spinal cord tumors.